“ why is 300,000 doses of drug on the shelf not considered an asset for the purpose of nasdaq”

At the risk of pointing out the obvious: a drug that you can’t sell (regardless of how much you have) isn’t worth anything - and in fact may have carrying costs that give it a negative value until it can be sold.

My hunch is we won’t see any progress on uplisting prior to an EUA.



Read More: https://investorshangout.com/post/newpost/605...z6h1cbkkhU